Clinical Trials Logo

Clinical Trial Summary

This study will test whether selected allogeneic bone marrow derived MSCs are safe by assessing the composite end point Biopsy Proven Acute Rejection (BPAR)/ graft loss at 12 months.

Clinical Trial Description

Kidney transplantation has improved survival and quality of life for patients with end-stage renal disease. However, despite advances in immunosuppressive therapy, long-term allograft survival outcomes have not improved over the last decade.

A promising novel therapeutic immunosuppressive option in the treatment of renal recipients with a profound effect on the fibrosis reaction is the clinical application of mesenchymal stromal cells (MSCs). Allogeneic MSCs offer the advantage of availability for clinical use without the delay required for expansion.

Although it is believed that allo MSCs are immune privileged, they could possibly elicit an anti-donor immune response, which may increase the incidence of rejection/ graft loss and impact the allograft survival on the long term. These safety issues should be studied before further studies are planned with allogeneic MSCs in the transplant setting.

MSCs are infused at a time point when immune suppression is lowered and the kidney is at increased risk for developing immune mediated injury. In addition, a large amount of the kidneys already has signs of fibrosis at this time point and MSCs might reduce the fibrosis which so importantly affects long term survival. MSCs will have no Human Leucocyte Antigen (HLA) sharing with the mismatches of the donor and the recipient should have no antibodies directed to the MSCs to reduce the anti-donor immune respons risk. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT02387151
Study type Interventional
Source Leiden University Medical Center
Status Active, not recruiting
Phase Phase 1
Start date March 2015
Completion date October 2018

See also
  Status Clinical Trial Phase
Completed NCT01298102 - Influenza A/H1N1/2009-adjuvanted Vaccine in Renal Disease Patients Phase 4
Completed NCT00225394 - Long Term Use of Valganciclovir for Prophylaxis of CMV Disease in Kidney and Pancreas Transplant Patients Phase 4
Active, not recruiting NCT01760356 - Study of PD/PK/PG Relationships of Tacrolimus and Cyclosporin in Liver Transplant Patients N/A
Recruiting NCT03425071 - Monitoring Concentration and Pharmacodynamic Effects of Tacrolimus in Peripheral Blood Lymphocytes of Kidney Transplant Recipients N/A
Recruiting NCT00558597 - Proteomics Analysis for Recognition of Acute Cellular Rejection After Lung Transplantation N/A
Completed NCT00743171 - Long-Term Study On Home Spirometry After Lung Transplantation N/A
Recruiting NCT00843960 - Medication Adherence Enhancement in Heart Transplant Recipients N/A
Active, not recruiting NCT01207141 - rATG Induction and Tacrolimus Monotherapy in Pediatric Liver Transplantation
Active, not recruiting NCT01211730 - Study of Glycemic Control on Liver Transplantation Outcomes Phase 4
Active, not recruiting NCT01208337 - Safety and Efficacy of Alemtuzumab in Pediatric Intestinal Transplantation Phase 2